Nephros, Inc. Receives the 2009 Frost & Sullivan Medical Device Patient Care Company of the ...(performance are based on assumptions and...),Health

Date:1/14/2009

performance, are based on assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond Nephros's control. Actual results may differ materially from the expectations contained in the forward-looking statements. Factors that may cause such differences include the risks that Nephros may not be able: (i) to maintain compliance with the AMEX's continued listing standards; (ii) to obtain funding if and when needed or on favorable terms; (iii) to continue as a going concern; (iv) to demonstrate in pre-clinical or clinical trials the anticipated efficacy, safety or cost savings of products that appeared promising to Nephros in research or clinical trials; (v) to obtain appropriate or necessary governmental approvals to achieve its business plan or effectively market its products; (vi) to have its technologies and products accepted in current or future target markets; or (viii) to secure or enforce adequate legal protection, including patent protection, for its products. More detailed information about Nephros and the risk factors that may affect the realization of forward-looking statements is set forth in Nephros's filings with the SEC, including Nephros's Annual Report on Form 10-KSB filed with the SEC for the fiscal year ended December 31, 2007, and Nephros's Quarterly Report on Form 10-Q for the periods ended September 30, 2008. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov/. Nephros does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

'/>"/>

SOURCE Nephros, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Med-Emerg International Inc. receives court approval for AIM Health Group arrangement
2. St. Marys Health System in Maine Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service
3. Alseres Pharmaceuticals, Inc. Receives Notice of Non-Compliance with Continued Listing Requirements
4. Dalcons Healthcare Communications Software Receives Internet Telephony Magazine Product of the Year Award
5. Nemours Center for Childhood Cancer Research Receives Over $1 Million in Grants for Cancer Research in 2008
6. WellPoint Receives Seven eHealthcare Leadership Awards
7. Ziosoft Receives FDA Clearance for CT Brain Perfusion Application
8. Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals
9. Guru Program Pioneered by Tom Gable Receives Official Registration from USPTO
10. Accuray Receives Prestigious Awards for 2008 Advertising Campaign
11. AGA Medical Receives Japanese Approval for AMPLATZER(R) Duct Occluder